



GE HealthCare

# FLYRCADO™ (flurpiridaz F 18) injection Reader Training

GE HealthCare offers an online electronic reader training program for the proper interpretation of Flyrcado positron emission tomography (PET) myocardial perfusion imaging (MPI) images.

SCAN HERE



Access reader training anytime through [www.readflyrcado.com](http://www.readflyrcado.com) or scan the QR code.

## Module 1:

### Introduction to Flyrcado PET MPI

Jamshid Maddahi, MD, FACC, MASNC  
David Geffen School of Medicine  
UCLA, Los Angeles, CA

## Module 2:

### Flyrcado PET MPI Protocols

René Packard, MD, PhD  
David Geffen School of Medicine  
UCLA, Los Angeles, CA

## Module 3:

### CT Imaging Flyrcado

James A. Case, PhD, MASNC  
Cardiovascular Imaging Technologies  
Kansas City, MO

## Module 4:

### Flyrcado Image Interpretation

Panithaya Chareonthaitawee, MD  
Mayo Clinic  
Rochester, MN

## Module 5:

### Flyrcado PET MPI - Putting it Together

Mouaz H. Al-Mallah, MD, MSc, MASNC  
Houston Methodist DeBakey Heart and  
Vascular Center, Houston, TX

Please see Important Safety Information on page 2 and full Prescribing Information [here](#).



## IMPORTANT SAFETY INFORMATION

### Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

### Contraindications

None

### Warnings and Precautions

- Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.
- Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

### Adverse Reactions

- Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence  $\geq$  2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

### Use in Specific Populations

**Pregnancy:** There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.

**Lactation:** Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.

**Pediatric Use:** Safety and effectiveness of FLYRCADO in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [GPV.drugsafety@gehealthcare.com](mailto:GPV.drugsafety@gehealthcare.com) or FDA at 800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Flyrcado Support Line: 800 729 0701**

**Medical Affairs: 800 654 0118**  
(option 2, then option 3) or  
[medical.affairs@gehealthcare.com](mailto:medical.affairs@gehealthcare.com)

**Customer Service: 800 292 8514**

[gehealthcare.com](http://gehealthcare.com)



© 2025 GE HealthCare

Flyrcado is a trademark of GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

February 2025 JB11433US